Last reviewed · How we verify
ICI35,868 (Diprivan)
Propofol is a rapid-acting intravenous sedative-hypnotic agent that enhances inhibitory GABAergic neurotransmission in the central nervous system.
Propofol is a rapid-acting intravenous sedative-hypnotic agent that enhances inhibitory GABAergic neurotransmission in the central nervous system. Used for Induction of general anesthesia, Maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care units.
At a glance
| Generic name | ICI35,868 (Diprivan) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Intravenous sedative-hypnotic |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | Phase 3 |
Mechanism of action
Propofol potentiates the effect of the inhibitory neurotransmitter GABA by binding to GABA-A receptors, leading to hyperpolarization of neuronal membranes and rapid onset of sedation and unconsciousness. It is commonly used for induction and maintenance of general anesthesia, as well as for sedation in intensive care settings.
Approved indications
- Induction of general anesthesia
- Maintenance of general anesthesia
- Sedation in mechanically ventilated patients in intensive care units
Common side effects
- Hypotension
- Apnea
- Bradycardia
- Injection site pain
- Hypertension
- Tachycardia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICI35,868 (Diprivan) CI brief — competitive landscape report
- ICI35,868 (Diprivan) updates RSS · CI watch RSS
- AstraZeneca portfolio CI